^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ERAS-801

    i
    Other names: ERAS-801, ERAS801, ERAS 801
    Company:
    Erasca, Katmai Pharma
    Drug class:
    EGFR inhibitor
    Related drugs:
    4ms
    ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial (clinicaltrials.gov)
    P1, N=10, Recruiting, Jonsson Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ERAS-801
    4ms
    ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Jonsson Comprehensive Cancer Center
    New P1 trial
    |
    ERAS-801
    8ms
    Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma (clinicaltrials.gov)
    P1, N=60, Recruiting, Memorial Sloan Kettering Cancer Center
    New P1 trial
    |
    temozolomide • ERAS-801 • ABBV-637 • mirzotamab clezutoclax (ABBV-155)
    10ms
    A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) (clinicaltrials.gov)
    P1, N=52, Active, not recruiting, Erasca, Inc. | Trial primary completion date: Jan 2025 --> Jun 2025
    Trial primary completion date
    |
    IDH wild-type
    |
    ERAS-801
    almost2years
    A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) (clinicaltrials.gov)
    P1, N=52, Active, not recruiting, Erasca, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    IDH wild-type
    |
    ERAS-801